We are so excited to share that we've won BIOTECanada's Gold Leaf Award 2024 for Promising Biotech Company of the Year! It's an honor to be recognized by BIOTECanada for the progress we've made in leveraging our #MachineLearning-enabled ReSOLVE™ platform to advance novel medicines, and we look forward to continuing this momentum. Thank you to our team, leaders, investors and partners for your dedication and support.
Ventus Therapeutics
Biotechnology Research
Waltham, Massachusetts 13,257 followers
Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal, QC.
Über uns
At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets. Others are building towards a future transformation of the drug development process … for Ventus, that future is already here. Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged or for which existing chemical matter leaves significant room for improvement. We are differentiated by our unique methods for modelling the properties of protein and water in motion. Optimal execution of these methods requires embedding our ReSOLVE platform with our world-class structural biology and chemistry teams. As our pipeline demonstrates, the ReSOLVE platform can find previously unknown pockets, better characterize known pockets, and solve the limitations of virtual screening, accelerating medicinal chemistry and structure-activity relationship (SAR) optimization. We are advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer, and also generating a library of chemical matter for elusive targets for future pipeline needs and business development. Our team includes experienced biopharmaceutical executives, scientists who have delivered multiple approved medicines, and luminary academics spanning the fields of structural biology, immunology, and computational chemistry.
- Website
-
http://www.ventustx.com
External link for Ventus Therapeutics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Waltham, Massachusetts
- Typ
- In Privatbesitz
- Gegründet
- 2019
Standorte
-
Primäre
100 Beaver St, Suite 202
Waltham, Massachusetts 02453, US
-
7150 Frederick-Banting
Montreal, Quebec H9S2A1, CA
Employees at Ventus Therapeutics
-
Jerel Davis
Managing Director at Versant Ventures
-
Amandine Chefson
Associate Director DMPK, at Ventus Therapeutics
-
Sammy Kim
Principal Scientist at Ventus Therapeutics
-
Dolca Thomas, MD
Biotech Executive; Board Member; R&D Leader; Physician Scientist; Coach/Mentor to Women and POC
Aktualisierungen
-
Ventus Therapeutics reposted this
🎉 Celebrating the Best in Canadian Biotech! 🎉 The BIOTECanada Gold Leaf Awards celebrate the innovation and strengths fueling our biotech ecosystem. After receiving numerous nominations of outstanding individuals, companies, and organizations, we are proud to announce the 2024 winners. Their remarkable achievements will be honoured at BIONATION in September. Meet the winners: 🏆 Biotech Company of the Year: Aspect Biosystems 🏆Promising Biotech Company of the Year: Ventus Therapeutics 🏆Game-Changing Industry Leadership: Clarissa Desjardins 🏆Leadership Award: Peter Zandstra Thank you to the Gold Leaf Awards selection committee Shermaine Tilley; Maxime Pesant CPA, CFA , Geneviève Guertin, John Norman, Penny Walsh-McGuire for their dedication and thoughtful review of this year's outstanding nominees. Read more about the Gold Leaf Awards, the categories, and the winners here: https://lnkd.in/eez5Mti6
-
“Our North Star is always going to be about developing therapeutics for people with high unmet needs who are suffering, “ said Ventus Chief Scientific Officer, Michael Crackower, on the most recent episode of Raising Health podcast. Dr. Crackower and Jason Burch joined Vineeta Agarwala, MD PhD, an a16z general partner, on Raising Health to discuss Ventus’ unique approach to #drugdiscovery through the power of water dynamics and our ReSOLVE™ platform. Listen below!
How can we identify previously undiscovered druggable protein pockets to design novel small molecule drugs? Michael Crackower, Chief Scientific Officer at Ventus Therapeutics, and Jason Burch believe the secret lies with water. Ventus' ReSOLVE platform incorporates dynamic water modeling into molecular dynamics simulations empowering their expert drug hunters to find new targets and design better small molecule drugs. The approach has led to a rare accomplishment - 3 clinical trials initiated within one year. Recently, Mike and Jason joined Vineeta Agarwala, MD PhD, a16z general partner, to discuss how this technology works and its potential impact in our industry. Listen on Raising Health: https://lnkd.in/dR5t7fP2
-
-
The Ventus team is excited to see our VP, Head of Drug Discovery, Stephane Ciblat, present at the Medicinal Chemistry Gordon Research Conferences in New London, New Hampshire this morning. Stéphane will be included in the “Challenging Medicinal Chemistry Dogma” section to discuss Ventus’ approach to drugging cGAS using our proprietary ReSOLVE™ platform, as well as take part in an important industry gathering of minds to learn more about the latest developments in the field. Learn more below and at https://lnkd.in/eunNmF9q
-
-
Ventus Therapeutics reposted this
For biotech startup Ventus Therapeutics, competing against Big Pharma can feel like David vs. Goliath. “How did David win the battle?” asks CEO Marcelo Bigal. “By being quick, by being fast, and by acting first. Basically that's it. Big Pharma has technologies, platforms, money, and critical mass. But they are slow.” Ventus is anything but slow: In just five years the company built a breakthrough platform for drug discovery, one that’s already yielded three clinical-stage therapies. In our latest Q&A, Bigal talks about competing with larger, better-resourced companies, putting patients first, and why having a shared mission is critical to success. https://lnkd.in/g_b6uYMq #biotech #medicine #innovation
-
-
We had such a wonderful time celebrating the grand opening of our new site in Montreal last week! This marked a special moment as we fondly remembered where #Ventus Therapeutics started just 5 years ago in Montreal and got to celebrate the growth and success that led to our move into our beautiful new home. The event was made even more special with the presence of our dedicated Ventus employees, their families, our supportive investors, esteemed board members, and our friends from the Montreal biotech community. Thank you to everyone who joined us. We look forward to all of the collaboration that will come in this space and working together toward discovering and designing novel #smallmoleculetherapeutics using our ML-enabled computational chemistry platform, ReSOLVE™. Read more: https://lnkd.in/eK6bHEA7
-
-
-
-
-
+2
-
-
Ventus Therapeutics reposted this
Finding cures for diseases like Parkinson’s means leaving no stone unturned. On the verge of developing a new kind of molecule to help combat the neurodegenerative condition, Ventus Therapeutics screened a documentary film about Parkinson’s for the entire company. The next day they invited a specialist to speak to everyone. On the third day, a patient with a severe form of Parkinson's shared his experience living with the disease. All three events were mandatory for employees, whether they were an accountant or a chemist. What was the impact? “Try telling someone at the company today that we’re giving up on Parkinson’s,” says CEO Marcelo Bigal. “They’re going to fight for it. The accountant is going to find money for Parkinson’s. This is our disease. Those events touched everyone at the company. They changed us.” Read our full Q&A with Bigal that spotlights how Ventus’s approach to drug discovery is unquestionably people-centered. https://lnkd.in/gveCgDTF #biotech #medicine #innovation
-
-
“ …we know exactly who we serve. We don't serve the target, we don't serve the protein, we don't serve the platform. We serve the patients who are struggling with a disease,” said Ventus CEO, Marcelo Bigal, M.D., Ph.D. in a recent interview with SoftBank Group Corp.’s Sōzō Insights Program. Marcelo talks about our people-centric operations in an open Q&A, diving deeper into his leadership style that’s driven our pipeline and company success for the past five years. Read more: https://lnkd.in/eSySgaVg